These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9326409)

  • 21. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
    AlDabbagh MA; Gitman MR; Kumar D; Humar A; Rotstein C; Husain S
    Am J Transplant; 2017 Mar; 17(3):770-781. PubMed ID: 27545492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
    Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
    Gao SZ; Chaparro SV; Perlroth M; Montoya JG; Miller JL; DiMiceli S; Hastie T; Oyer PE; Schroeder J
    J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
    Funch DP; Walker AM; Schneider G; Ziyadeh NJ; Pescovitz MD
    Am J Transplant; 2005 Dec; 5(12):2894-900. PubMed ID: 16303002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD
    Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG; Tan MYQ; Quak SH; Aw MM
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study.
    Ville S; Imbert-Marcille BM; Coste-Burel M; Garandeau C; Meurette A; Cantarovitch D; Giral M; Hourmant M; Blancho G; Dantal J
    Transpl Int; 2018 May; 31(5):484-494. PubMed ID: 29057508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
    Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
    Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?
    Abecassis MM; Koffron AJ; Kaplan B; Buckingham M; Muldoon JP; Cribbins AJ; Kaufman DB; Fryer JP; Stuart J; Stuart FP
    Transplantation; 1997 Jan; 63(2):275-9. PubMed ID: 9020330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of induction therapy on the risk of posttransplant lymphoproliferative disorder in adult kidney transplant recipients with donor-recipient serological Epstein-Barr virus mismatch.
    Attieh RM; Wadei HM; Mao MA; Mao SA; Pungpapong S; Taner CB; Jarmi T; Cheungpasitporn W; Leeaphorn N
    Am J Transplant; 2024 Aug; 24(8):1486-1494. PubMed ID: 38447887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children.
    Green M; Bueno J; Rowe D; Mazariegos G; Qu L; Abu-Almagd K; Reyes J
    Transplantation; 2000 Aug; 70(4):593-6. PubMed ID: 10972215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.